SCHEMBL10067347

SCHEMBL10067347

Cc1c(C)n(CC(=O)N2CCCCC2C)c2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.64
MAPK1 P28482 1/20 0.60
KMT2A Q03164 3/20 0.56
CYP1A2 P05177 2/20 0.56
CYP3A4 P08684 2/20 0.56
CYP2D6 P10635 2/20 0.56
CYP2C19 P33261 2/20 0.56
MEN1 O00255 2/20 0.56
CYP2C9 P11712 1/20 0.56
CHRM2 P08172 1/20 0.52
ALDH1A1 P00352 5/20 0.52
L3MBTL1 Q9Y468 2/20 0.50
MAPT P10636 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
USP2 O75604 2/20 0.50
LMNA P02545 2/20 0.50
TP53 P04637 1/20 0.50
GLA P06280 1/20 0.50
ATM Q13315 1/20 0.50
RAB9A P51151 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10067342 0.81 LMNA (0.72) TSHRMAPK1CYP1A2CYP3A4CYP2D6
SCHEMBL10067355 0.80 LMNA (0.70) TSHRMAPK1ALDH1A1L3MBTL1MAPT
SCHEMBL10067354 0.80 LMNA (0.70) TSHRMAPK1ALDH1A1L3MBTL1MAPT
SCHEMBL10067353 0.79 NPSR1 (0.62) TSHRKMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL10067278 0.77 TSHR (0.47) TSHRMAPK1KMT2ACYP1A2CYP3A4
SCHEMBL24479586 0.72 KMT2A (0.74) TSHRKMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL11601199 0.72 ALDH1A1 (0.71) MAPK1KMT2AMEN1ALDH1A1L3MBTL1
SCHEMBL14448728 0.72 ALDH1A1 (0.62) MAPK1KMT2AMEN1ALDH1A1MAPT
SCHEMBL11605552 0.70 ALDH1A1 (0.60) MAPK1KMT2AMEN1ALDH1A1MAPT
SCHEMBL13280179 0.70 HPGD (0.74) MAPK1CHRM2ALDH1A1NPSR1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 US disclosed
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 US disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 US disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer FLI1, IKZF3, IKZF2 TSHR 3689/4885MAPK1 3440/4885KMT2A 377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.